Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Autor: C Cheneau, S Barthier, J Lemonnier, Fabrice Andre, C Dubot, L Teixeira, A Escande, T De La Motte Rouge, T Petit, L Arnould, Laurent Arnould, Suzette Delaloge, Jerome Lemonnier, A Marti, L Stefani, F Berger, C Levy, P Barthelemy, S Nguyen, M Gardner, A Lortholary, François-Clément Bidard, J Plaza, L Joly, Thibault de la Motte Rouge, F Andre, I Bièche, C Alleaume, R Sabatier, B Lucas, Ivan Bieche, O Derbel, L Venat-Bouvet, F Del Piano, Florian Clatot, Anne-Claire Hardy-Bessard, Frédérique Berger, Margaux Marce, Thomas Bachelot, Anne Pradines, Jean-Luc Canon, Sandrine Marques, M Achille, H Ammarguellat, O Arsene, T Bachelot, C Bernard-Marty, F-C Bidard, N Bonichon-Lamichhane, N Bonnin, R Bouaita, A Boudrant, V-A Brunel, C Chakiba, F Clatot, F Dalenc, A De Gramont, L Deiana, C Delbaldo, V Delecroix, H Desclos, V D'Hondt, N Dohollou, J-M Ferrero, C Foa, J-S Frenel, C Garnier Tixidre, D Genet, O Gisserot, M Gozy, C Greilsamer, J Grenier, F Guinet, A-C Hardy-Bessard, J-P Jacquin, E Lachaier, S Ladoire, A-P Laurenty, R Le Scodan, N Leduc, E Legouffe, C Levache, F Lorchel, N Marques, J Medioni, A Melis, D Mille, D Mollon, L Moreau, I Moullet, M-A Mouret-Reynier, A Najem, H Orfeuvre, J-F Paitel, B Pistilli, C Riedl, P Soulie, D Spaeth, F Trouboul, C Valmar, H Vegas, A Zannetti, FC Bidard, S Delaloge, A Pradines, JL Canon, S Marques

Publikováno v: BMJ Open, Vol 12, Iss 3 (2022)

Introduction The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2−) advanced breast cancer. Howev

Externí odkaz: https://doaj.org/article/8faf6bbc845f4ceeb90674dd08e198da

Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation

Autor: J.-S. Frenel, A. Lusque, S. Delaloge, J.-M. Ferrero, T. Bachelot, I. Desmoulins, C. Levy, J.-C. Eymard, A. Gonçalves, A. Patsouris, M. A. Mouret Reynier, M. J.-C. Thery, T. Petit, L. Cabel, L. Uwer, M. Debled, M. Chevrot, A. Mailliez, W. Jacot, T. de La Motte Rouge

Publikováno v: British Journal of Cancer. 128:2072-2080

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40812445ccdae72ddca53e16aa782a79
https://doi.org/10.1038/s41416-023-02248-4

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)

Autor: B. Pistilli, N. Ibrahimi, M. Lacroix-Triki, V. D'Hondt, C. Vicier, J-S. Frenel, F. Dalenc, T. Bachelot, M-A. Benderra, D. Loirat, A. Ducoulombier, D. Mayeur, G.B. Nachabeh, K. Serhal, N. Corcos, D. Sellami, S. Michiels, F. André, M.F. Mosele, G. Montagnac

Publikováno v: ESMO Open. 8:101378

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6d2b9961f071eceafefa27738c71e9b
https://doi.org/10.1016/j.esmoop.2023.101378